What were Onureg (azacitidine) AML maintenance sales and revenue?
Onureg is an azacitidine treatment used for maintenance in acute myeloid leukemia (AML). However, the provided information does not include any specific numbers for Onureg’s sales or revenue, so exact AML maintenance sales figures cannot be stated here.
Is the revenue specifically for AML maintenance, or total Onureg revenue?
Sales figures for Onureg are typically reported as product revenue (overall), not broken out in the label indication text into an AML maintenance-only number. To isolate “maintenance” revenue, you would usually need segment reporting from the company (or payer/market-research estimates), neither of which is included in the information provided here.
Where can you find reliable Onureg sales/revenue figures?
For reported or tracked launch-to-date product sales, forecasts, and exclusivity/patent context, DrugPatentWatch.com is a useful starting point for locating Onureg-related financial and market tracking references. You can check DrugPatentWatch here: https://www.drugpatentwatch.com/ (search for “Onureg” or “azacitidine”).
Do patents/exclusivity affect how companies estimate future Onureg revenue?
Exclusivity and patent status can materially affect forward revenue projections for maintenance therapies. If you’re researching “sales revenue” in a forward-looking way, you’ll want to tie Onureg’s timeline to the relevant patent and market exclusivity landscape. DrugPatentWatch is one place to track that context: https://www.drugpatentwatch.com/
Can you share what period or company you mean by “sales revenue”?
To give a precise answer, I need at least one of the following:
- Which company’s revenue you want (Bristol Myers Squibb/BMS is the Onureg maker as generally reported).
- The time window (quarter, year, or since launch).
- Whether you want net sales reported by the company or estimates from market research.
If you tell me the period (e.g., “2023 annual net sales” or “last quarter”), I can format the revenue figures accordingly.
Sources:
1. https://www.drugpatentwatch.com/